50% off all subscriptions! ... left. Order NowOrder Now

Weaker Stock
Today CLDX ranks #13068 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Celldex Therapeutics Stock Forecast NASDAQ:CLDX

$39.61 (-3.67%)

Volume: 434k

Closed: Nov 26, 2021

Hollow Logo Score: -6.028

Celldex Therapeutics Stock Forecast

$39.61 (-3.67%)

Volume: 434k

Closed: Nov 26, 2021

Score Hollow Logo -6.028
Which way will CLDX go? Request
Key Stats
P/E Ratio -25.58
Beta 1.17
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 80 ] RSI14 is 28 and the stock is currently not being overbought or oversold

Evaluation of Celldex Therapeutics stock downgraded after the last trading session.
(Updated on Nov 26, 2021)

Sell candidate since 2021-11-22 Loss -4.65%

The Celldex Therapeutics stock price fell by -3.67% on the last day (Friday, 26th Nov 2021) from $41.12 to $39.61. During the day the stock fluctuated 8.78% from a day low at $38.03 to a day high of $41.37. The price has fallen in 6 of the last 10 days and is down by -10.79% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -21 thousand shares and in total, 434 thousand shares were bought and sold for approximately $17.21 million.

The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -24.91% during the next 3 months and, with a 90% probability hold a price between $28.63 and $33.15 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Signals & Forecast

There are few to no technical positive signals at the moment. The Celldex Therapeutics stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $41.78 and $45.39. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Wednesday, November 03, 2021, and so far it has fallen -17.26%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

Support, Risk & Stop-loss

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $3.34 between high and low, or 8.78%. For the last week, the stock has had a daily average volatility of 5.79%.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Celldex Therapeutics stock A Buy?

Celldex Therapeutics holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate.

Current score: -6.028

Predicted Opening Price for Celldex Therapeutics of Monday, November 29, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price November 29, 2021 Current price
$39.67 $39.61 (Undervalued)
Strong Sell Candidate Downgraded

Remember To Visit Our YouTube Channel

Analyst Ratings

On Sep 17, 2021 "Jefferies Financial Group" gave "" rating for CLDX. The price target was set to $53.28+0.1%.

Volatility and Risk
Daily Average Volatility: 5.79 %
Overall Risk: Very High High Medium Low Very Low
5.79 %
Daily Average Volatility
Overall Risk

Very High
Very Low

Support & Resistance

Resistance: $45.28
Price: $39.61
No Support Found

CLDX Insider Trading Show all Trades



Last 100 transactions
Buy: 2 504 111 | Sell: 140 035 (Shares)
Date Action Amount Person Type
Nov 15, 2021 Sell 3 750 Martin Samuel Bates Incentive Stock Option (Right to Buy)
Nov 15, 2021 Sell 3 250 Martin Samuel Bates Incentive Stock Option (Right to Buy)
Nov 15, 2021 Sell 2 048 Martin Samuel Bates Common Stock
Nov 15, 2021 Sell 7 452 Martin Samuel Bates Common Stock
Nov 15, 2021 Buy 3 750 Martin Samuel Bates Common Stock
Show all Insider Trades


Last 100 transactions
Buy: 2 504 111 | Sell: 140 035 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 43.01 8.58 %
41.73 5.36 %
40.95 3.37 %
Current price: 39.61
Support 38.39 -3.07 %
37.61 -5.06 %
36.33 -8.28 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 47.75 20.55 %
46.88 18.35 %
45.28 14.31 %
Current price 39.61
Support 0 .
0 .
0 .

Click to get the best stock tips daily for free!

About Celldex Therapeutics

Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. The company’s lead drug candidates comprise Rintega (CDX-110), a therapeutic vaccine in Phase III clinical studies for the treatment of glioblastoma patients that express an epidermal growth factor receptor variant III, as well as in Phase II study for the treatment of recurrent gliobl... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE